Target Price | €44.83 |
Price | €35.98 |
Potential | 24.61% |
Number of Estimates | 19 |
19 Analysts have issued a price target Qiagen 2026 . The average Qiagen target price is €44.83. This is 24.61% higher than the current stock price. The highest price target is €53.04 47.42% , the lowest is €37.88 5.29% . | |
A rating was issued by 22 analysts: 11 Analysts recommend Qiagen to buy, 11 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Qiagen stock has an average upside potential 2026 of 24.61% . Most analysts recommend the Qiagen stock at Buy or hold. |
19 Analysts have issued a sales forecast Qiagen 2025 . The average Qiagen sales estimate is €1.9b . This is 2.36% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €2.0b 8.33% , the lowest is €1.8b 2.49% .
This results in the following potential growth metrics:
2024 | €1.8b | 0.60% |
---|---|---|
2025 | €1.9b | 2.38% |
2026 | €2.0b | 6.29% |
2027 | €2.1b | 7.98% |
2028 | €2.3b | 7.73% |
2029 | €2.6b | 11.18% |
18 Analysts have issued an Qiagen EBITDA forecast 2025. The average Qiagen EBITDA estimate is €710m . This is 10.01% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €781m 20.94% , the lowest is €615m 4.75% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | €645m | 7.27% |
---|---|---|
2025 | €710m | 10.05% |
2026 | €765m | 7.67% |
2027 | €828m | 8.29% |
2028 | €891m | 7.52% |
2029 | €989m | 11.08% |
2024 | 35.30% | 6.62% |
---|---|---|
2025 | 37.94% | 7.49% |
2026 | 38.43% | 1.29% |
2027 | 38.54% | 0.29% |
2028 | 38.47% | 0.18% |
2029 | 38.44% | 0.08% |
12 Qiagen Analysts have issued a net profit forecast 2025. The average Qiagen net profit estimate is €404m . This is 449.57% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €472m 542.51% , the lowest is €343m 366.42% .
This results in the following potential growth metrics and future Net Margins:
2024 | €75.6m | 75.86% |
---|---|---|
2025 | €404m | 433.87% |
2026 | €446m | 10.39% |
2027 | €495m | 11.12% |
2028 | €544m | 9.79% |
2029 | €608m | 11.88% |
2024 | 4.14% | 76.01% |
---|---|---|
2025 | 21.57% | 421.50% |
2026 | 22.40% | 3.85% |
2027 | 23.05% | 2.90% |
2028 | 23.49% | 1.91% |
2029 | 23.64% | 0.64% |
12 Analysts have issued a Qiagen forecast for earnings per share. The average Qiagen EPS is €1.87 . This is 450.00% higher than earnings per share in the financial year 2024. The highest EPS forecast is €2.18 541.18% , the lowest is €1.59 367.65% .
This results in the following potential growth metrics and future valuations:
2024 | €0.35 | 75.86% |
---|---|---|
2025 | €1.87 | 434.29% |
2026 | €2.06 | 10.16% |
2027 | €2.29 | 11.17% |
2028 | €2.52 | 10.04% |
2029 | €2.82 | 11.90% |
Current | 106.64 | 292.78% |
---|---|---|
2025 | 19.26 | 81.94% |
2026 | 17.44 | 9.45% |
2027 | 15.70 | 9.98% |
2028 | 14.30 | 8.92% |
2029 | 12.78 | 10.63% |
Based on analysts' sales estimates for 2025, the Qiagen stock is valued at an EV/Sales of 4.34 and an P/S ratio of 4.15 .
This results in the following potential growth metrics and future valuations:
Current | 4.44 | 9.76% |
---|---|---|
2025 | 4.34 | 2.29% |
2026 | 4.08 | 5.91% |
2027 | 3.78 | 7.39% |
2028 | 3.51 | 7.18% |
2029 | 3.16 | 10.05% |
Current | 4.25 | 8.40% |
---|---|---|
2025 | 4.15 | 2.30% |
2026 | 3.91 | 5.91% |
2027 | 3.62 | 7.39% |
2028 | 3.36 | 7.17% |
2029 | 3.02 | 10.05% |
Analyst | Rating | Action | Date |
---|---|---|---|
Redburn Atlantic |
Buy
➜
Neutral
|
Downgrade | Apr 04 2025 |
Baird |
Outperform
➜
Neutral
|
Downgrade | Feb 19 2025 |
UBS |
Neutral
➜
Neutral
|
Unchanged | Feb 07 2025 |
Morgan Stanley |
Overweight
➜
Equal-Weight
|
Downgrade | Jan 06 2025 |
HSBC |
Buy
➜
Hold
|
Downgrade | Oct 17 2024 |
Analyst Rating | Date |
---|---|
Downgrade
Redburn Atlantic:
Buy
➜
Neutral
|
Apr 04 2025 |
Downgrade
Baird:
Outperform
➜
Neutral
|
Feb 19 2025 |
Unchanged
UBS:
Neutral
➜
Neutral
|
Feb 07 2025 |
Downgrade
Morgan Stanley:
Overweight
➜
Equal-Weight
|
Jan 06 2025 |
Downgrade
HSBC:
Buy
➜
Hold
|
Oct 17 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.